Free Trial

Zai Lab (ZLAB) Competitors

-1.14 (-5.98%)
(As of 05/24/2024 ET)


Should you be buying Zai Lab stock or one of its competitors? The main competitors of Zai Lab include Rocket Pharmaceuticals (RCKT), Arvinas (ARVN), Amneal Pharmaceuticals (AMRX), Geron (GERN), Deciphera Pharmaceuticals (DCPH), Vera Therapeutics (VERA), Amphastar Pharmaceuticals (AMPH), Evotec (EVO), Catalyst Pharmaceuticals (CPRX), and Agios Pharmaceuticals (AGIO). These companies are all part of the "pharmaceutical preparations" industry.

Zai Lab vs.

Zai Lab (NASDAQ:ZLAB) and Rocket Pharmaceuticals (NASDAQ:RCKT) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their community ranking, institutional ownership, dividends, media sentiment, valuation, analyst recommendations, profitability, earnings and risk.

In the previous week, Rocket Pharmaceuticals had 6 more articles in the media than Zai Lab. MarketBeat recorded 13 mentions for Rocket Pharmaceuticals and 7 mentions for Zai Lab. Zai Lab's average media sentiment score of 0.39 beat Rocket Pharmaceuticals' score of 0.20 indicating that Zai Lab is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Zai Lab
2 Very Positive mention(s)
1 Positive mention(s)
3 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Rocket Pharmaceuticals
3 Very Positive mention(s)
3 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)

Rocket Pharmaceuticals has lower revenue, but higher earnings than Zai Lab. Rocket Pharmaceuticals is trading at a lower price-to-earnings ratio than Zai Lab, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Zai Lab$266.72M6.67-$334.62M-$3.49-5.13
Rocket PharmaceuticalsN/AN/A-$245.60M-$2.87-7.46

Rocket Pharmaceuticals has a net margin of 0.00% compared to Zai Lab's net margin of -116.45%. Zai Lab's return on equity of -40.21% beat Rocket Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
Zai Lab-116.45% -40.21% -32.48%
Rocket Pharmaceuticals N/A -53.10%-46.90%

Zai Lab has a beta of 1.11, meaning that its share price is 11% more volatile than the S&P 500. Comparatively, Rocket Pharmaceuticals has a beta of 1.12, meaning that its share price is 12% more volatile than the S&P 500.

41.7% of Zai Lab shares are held by institutional investors. Comparatively, 98.4% of Rocket Pharmaceuticals shares are held by institutional investors. 5.2% of Zai Lab shares are held by company insiders. Comparatively, 31.1% of Rocket Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Rocket Pharmaceuticals received 151 more outperform votes than Zai Lab when rated by MarketBeat users. Likewise, 72.18% of users gave Rocket Pharmaceuticals an outperform vote while only 63.58% of users gave Zai Lab an outperform vote.

Zai LabOutperform Votes
Underperform Votes
Rocket PharmaceuticalsOutperform Votes
Underperform Votes

Zai Lab currently has a consensus price target of $64.22, indicating a potential upside of 258.39%. Rocket Pharmaceuticals has a consensus price target of $52.13, indicating a potential upside of 143.35%. Given Zai Lab's stronger consensus rating and higher probable upside, research analysts clearly believe Zai Lab is more favorable than Rocket Pharmaceuticals.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Zai Lab
0 Sell rating(s)
0 Hold rating(s)
5 Buy rating(s)
0 Strong Buy rating(s)
Rocket Pharmaceuticals
0 Sell rating(s)
1 Hold rating(s)
8 Buy rating(s)
0 Strong Buy rating(s)


Rocket Pharmaceuticals beats Zai Lab on 10 of the 17 factors compared between the two stocks.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ZLAB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

ZLAB vs. The Competition

MetricZai LabPharmaceutical IndustryMedical SectorNASDAQ Exchange
Market Cap$1.78B$6.81B$5.20B$8.06B
Dividend YieldN/A2.67%2.83%3.93%
P/E Ratio-5.1321.27152.1518.19
Price / Sales6.67259.912,464.4379.80
Price / CashN/A36.7936.3031.61
Price / Book2.335.865.444.60
Net Income-$334.62M$132.39M$106.24M$214.07M
7 Day Performance-7.63%-2.40%-1.33%-1.08%
1 Month Performance14.43%1.64%2.76%3.20%
1 Year Performance-47.03%-6.49%3.39%7.84%

Zai Lab Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
Rocket Pharmaceuticals
4.6959 of 5 stars
2.7911 of 5 stars
Amneal Pharmaceuticals
2.8428 of 5 stars
+182.9%$2.10B$2.39B-12.237,700Positive News
3.8546 of 5 stars
+10.8%$2.18B$240,000.00-10.51141Positive News
Deciphera Pharmaceuticals
3.2477 of 5 stars
+76.3%$2.09B$174.91M-11.51355Positive News
High Trading Volume
Vera Therapeutics
0.4551 of 5 stars
Amphastar Pharmaceuticals
4.899 of 5 stars
-1.9%$1.99B$644.40M14.291,761Analyst Forecast
Analyst Revision
1.5363 of 5 stars
N/A$1.97B$791.73M0.004,952Analyst Forecast
Analyst Revision
News Coverage
Gap Down
High Trading Volume
Catalyst Pharmaceuticals
4.9293 of 5 stars
+35.1%$1.95B$411.35M30.54167Positive News
Agios Pharmaceuticals
2.8855 of 5 stars
+18.0%$1.94B$26.82M-5.40383Analyst Downgrade
Analyst Revision

Related Companies and Tools

This page (NASDAQ:ZLAB) was last updated on 5/25/2024 by Staff

From Our Partners